No phaseCompleted
Intranasal Oxytocin for Methamphetamine Withdrawal in Women (mOXY)
An Open Label Pilot Study of Intranasal Oxytocin for Methamphetamine Withdrawal in Women
- Sponsor
- Turning Point (Academic or other)
- Enrollment
- 10 enrolled
- Conditions
- Methamphetamine Use Disorder
- Interventions
- Oxytocin nasal spray
- Ages
- adults, older adults
- Registry
- NCT05760807
Full record on ClinicalTrials.gov
From the registry
Methamphetamine use disorder (MUD) is a significant public health concern with burden to individuals, families and health systems estimated to cost over $5 billion annually in Australia. In 2016/17 there were 49,670 Australian treatment episodes for MUD, the first step of which typically involves inpatient withdrawal. Currently there are no approved medications to help manage methamphetamine withdrawal and consequently many people drop out of treatment prematurely, leaving them vulnerable to relapse. Oxytocin is a candidate medication that has the potential to increase treatment retention, reduce withdrawal syndrome severity, increase post-withdrawal treatment engagement and reduce relapse rates. The aim of this pilot study is to investigate whether intranasal oxytocin can improve withdrawal treatment outcomes in adult women with MUD. The study will examine the feasibility of intranasal oxytocin as a treatment for methamphetamine withdrawal in women. This will be explored by assessing length of stay in residential withdrawal, withdrawal symptom severity, post-discharge treatment…
Primary outcomes
- Feasibility assessment
History
Last registry update
Primary completion
Started
Registered